Tag: GlobeNewswire

MILWAUKEE, Oct. 01, 2026 (GLOBE NEWSWIRE) — Brady Corporation (NYSE: BRC) (“Brady”) announced today that it sold its Securimed SAS (“Securimed”) business for approximately EUR 53 million (approximately USD 59 million) to Safe Life International (“Safe Life”).

Securimed is a supplier and distributor of customized first-aid kits, supplies, and related healthcare products including personal protection, diagnosis materials and products for emergency response. Customers include administrative and corporate health and safety departments predominantly located in France. Securimed was founded in 1986 and is headquartered in Cappelle-la-Grande, France.

“Securimed is a well-known French supplier of healthcare and other safety-related products, which has delivered strong results since Brady’s acquisition in 2010. This transaction places Securimed with high-quality ownership in Safe Life, while allowing Brady to continue to focus on its offering of specialty identification and intelligent productivity solutions and driving long-term value for our shareholders,” said Brady’s President and Chief Executive Officer, Vineet Nargolwala.

Brady Corporation (NYSE: BRC) is a global industrial technology company and a leading provider of identification, safety, and productivity solutions that help organizations of all sizes to identify, connect, protect, track, and optimize what matters most. By combining trusted identification technologies with advanced data capture, enterprise mobility, software and workflow solutions, Brady’s comprehensive offerings enable its customers to improve safety, productivity, accuracy, and operational performance across their most critical functions and in the world’s most demanding environments. For more than 110 years, Brady has established trust and demonstrated its commitment to innovation, serving customers across manufacturing, logistics, healthcare, electronics, telecommunications, aerospace, construction, and other key industries, to make their work safer, smarter, and more connected. Headquartered in Milwaukee, Wisconsin, Brady employs approximately 9,300 people worldwide. Brady stock trades on the New York Stock Exchange under the symbol BRC. Learn more at www.bradycorp.com.

In this release, statements that are not reported financial results or other historic information are “forward-looking statements.” These forward-looking statements relate to, among other things, statements about the success of the acquisition, including anticipated benefits and synergies of the transaction, future opportunities for the combined company, and any other statements regarding the establishment of a new reporting segment for the IPS business, the combined company’s future operations and future financial position, anticipated economic activity, business strategies, targets, future earnings, anticipated growth, market opportunities, debt levels and cash flows, competition and other expectations and estimates for future periods including plans and objectives of management for future operations.

The use of words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project,” “plan” or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements by their nature address matters that are, to different degrees, uncertain and are subject to risks, assumptions, and other factors, some of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. For the Company, uncertainties arise from: the ability of the Company and the IPS business to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; potential difficulties integrating the IPS business, or the costs of integrating the IPS business exceeding original estimates; failure of the Company to achieve the anticipated benefits and synergies of the transaction identified in this release on the timeline indicated or at all; the establishment of a new reporting segment for the IPS business; increased cost of materials, labor, material shortages and supply chain disruptions, including as a result of tariffs or other impacts of the global trade environment; decreased demand for the Company’s products; the Company’s ability to compete effectively or to successfully execute our strategy; the Company’s ability to develop technologically advanced products that meet customer demands; the Company’s ability to identify, integrate and grow acquired companies, and to manage contingent liabilities from divested businesses; difficulties in protecting the Company’s websites, networks, and systems against security breaches; extensive regulations by U.S. and non-U.S. governmental and self-regulatory entities; risks associated with the loss of key employees; litigation, including product liability claims; global climate change and environmental regulations; foreign currency fluctuations; our indebtedness, financial condition and fulfillment of obligations thereunder; the ability to service our indebtedness; changes in tax legislation and tax rates; potential write-offs of goodwill and other intangible assets; differing interests of voting and non-voting shareholders and changes in the regulatory and business environment around dual-class voting structures; numerous other matters of national, regional and global scale, including major public health crises and government responses thereto and those of a political, economic, business, competitive, and regulatory nature contained from time to time in the Company’s U.S. Securities and Exchange Commission filings, including, but not limited to, those factors listed in the “Risk Factors” section within Item 1A of Part I of the Company’s Form 10-K for the year ended July 31, 2026.

These uncertainties may cause the Company’s actual future results to be materially different than those expressed in its forward-looking statements. The Company does not undertake to update its forward-looking statements except as required by law.

For More Information:
Investor contact: Ann Thornton 414-438-6887
Media contact: Kate Venne 414-358-5176

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $2.605 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.

Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.

About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​ 

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact: 
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION TO THE UNITED STATES.

SASKATOON, Saskatchewan, Oct. 01, 2026 (GLOBE NEWSWIRE) — GFG Resources Inc. (TSXV: GFG | OTCQB: GFGSF) (“GFG” or the “Company”) is pleased to announce that it has entered into an agreement with Paradigm Capital Inc. (“Paradigm”), as sole agent and bookrunner (the “Agent”), in connection with a “best efforts” private placement offering for aggregate gross proceeds of up to approximately C$7.0 million (the “Offering”).

The Offering will consist of:

1. Units: up to 5,264,000 units of the Company (the “HD Units”) at a price of C$0.19 per HD Unit for gross proceeds of up to approximately C$1.0 million, with each HD Unit consisting of one non-flow-through common share of the Company (a “Common Share”) and one-half of one non-flow-through Common Share purchase warrant (each whole warrant, a “Warrant”) on a non-flow-through basis; and

2. Flow-Through Securities: (i) common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”) (the “FT Shares”) at a price of C$0.22 per FT Share and (ii) premium units of the Company (“Premium FT Units”), each consisting of one FT Share and one-half of one flow-through Warrant, at a price of C$0.266 per Premium FT Unit, each of which will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Tax Act  in any combination to raise aggregate gross proceeds of up to approximately C$6.0 million.

Each whole Warrant shall be exercisable to acquire one additional non-flow-through Common Share at an exercise price of $0.285 for a period of two years.

In addition, the Company has granted the Agent an option to sell up to $1,050,042 of additional securities (the “Agent’s Option”) on the same terms and conditions, exercisable in whole or in part at any time up to 48 hours prior to the closing date of the Offering. The Agent’s Option may be exercised for FT Shares, Premium FT Units or HD Units, or a combination thereof (at the discretion of the Agent) at the respective offering prices.

The HD Units, Premium FT Units and FT Shares are collectively referred to as the “Offered Securities”. The terms “Offering”, “Offered Securities”, “FT Shares”, “Premium FT Units” and “HD Units” include the additional FT Shares, Premium FT Units and HD Units that may be issued on the exercise of the Agent’s Option, if any.

An amount equal to the gross proceeds (the “Gross Proceeds”) from the issuance of the Premium FT Units and FT Shares will be used to incur “Canadian exploration expenses” as defined in the Tax Act that will qualify as “flow-through mining expenditures”, as defined in subsection 127(9) of the Tax Act (the “Qualifying Expenditures”). The Qualifying Expenditures will be incurred on or before December 31, 2027 and an amount of such Qualifying Expenditures equal to the Gross Proceeds will be renounced by the Company to the subscribers of the Premium FT Units and FT Shares with an effective date no later than December 31, 2026. The proceeds from the sale of the HD Units will be used for general corporate and working capital purposes as described in the Offering Document (as defined below).

The Offering is expected to close on or about October 23, 2026, or such other date as the Company and the Agent may agree (the “Closing Date”), and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including acceptance of the TSX Venture Exchange (the “TSXV”).

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), the FT Shares, HD Units and Premium FT Units will be offered for sale to purchasers’ resident in Canada and/or other qualifying jurisdictions pursuant to the Listed Issuer Financing Exemption under Part 5A of NI 45-106 and in reliance on the amendments to Part 5A of NI 45-106 set forth in Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (collectively, the “Listed Issuer Financing Exemption”). Pursuant to the Listed Issuer Financing Exemption, the FT Shares, HD Units and Premium FT Units issued to subscribers will not be subject to a hold period pursuant to applicable Canadian securities laws. There is an offering document on Form 45-106F19 related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.gfgresources.com. Prospective investors should read this offering document before making an investment decision. 

It is anticipated that certain insiders of the Company will participate in the Offering. Such participation will be considered to be a “related party transaction” within the meaning of Multilateral Instrument 61-101-Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company intends to rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of any related party participation in the Offering as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it will involve interested parties, is expected to exceed 25% of the Company’s market capitalization (as determined under MI 61-101).

At the Closing Date, the Company has agreed to pay the Agent a cash commission equal to 6.0% of the gross proceeds raised in connection Offering. GFG may nominate certain purchasers of the Offered Securities under the Offering (the “President’s List”). The Agent shall receive a cash fee equal to 3.0% of the gross proceeds raised from the Company’s President’s List.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States unless an exemption from such registration is available.

About GFG Resources Inc.
GFG is a North American precious metals exploration company focused on district-scale gold opportunities in the Timmins Gold District of Ontario, Canada. The Company controls three highly prospective gold projects within one of the world’s most established gold camps.

GFG’s exploration strategy is focused on advancing the Aljo gold system, systematically generating and testing new discovery opportunities across the Goldarm Property and maintaining significant exposure to the advancement of the Pen Gold Project through its strategic earn-in agreement with Barrick.

For further information, please contact:
Brian Skanderbeg, President & CEO
or
Marc Lepage, Vice President, Business Development
Phone: (306) 931-0930
Email: info@gfgresources.com
Website: www.gfgresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING INFORMATION
All statements, other than statements of historical fact, contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (referred to herein as “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the Offering (including the completion of the Offering on the terms and timeline as announced or at all, the tax treatment of the Premium FT Units and the FT Shares, the timing to renounce all Qualifying Expenditures in favour of the subscribers and use of proceeds of the Offering), the Company’s future exploration plans with respect to its property interests and the timing thereof, the prospective nature of the projects, future price of gold, success of exploration activities and metallurgical test work, permitting time lines, currency exchange rate fluctuations, requirements for additional capital, government regulation of exploration work, environmental risks, unanticipated reclamation expenses, title disputes or claims and limitations on insurance coverage. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. 

All forward-looking statements are based on various assumptions, including, without limitation, the expectations and beliefs of management, the assumed long-term price of gold, that the Company will receive required permits and access to surface rights, that the Company can access financing, appropriate equipment and sufficient labour, and that the political environment within Canada will continue to support the development of mining projects. In addition, the similarity or proximity of other gold deposits to the Company’s projects is not necessary indicative of the geological setting, alteration and mineralization of the Goldarm Property and the Dore Gold Project.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of GFG to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: that the Offering will not close on the anticipated timeline or at all on the anticipated terms; that the Company will use the net proceeds of the Offering as anticipated; that the Company will receive all necessary approvals in respect of the Offering, market uncertainty and the results of the Company’s anticipated work programs actual results of current exploration activities; environmental risks; future prices of gold; operating risks; accidents, labour issues and other risks of the mining industry; availability of capital, delays in obtaining regulatory approvals or financing; receipt of applicable regulatory approvals and other risks and uncertainties. These risks and uncertainties and the additional risks described in the Company’s most recently filed annual and interim MD&A are not and should not be construed as being exhaustive. 

Although GFG has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management’s current expectations and plans and allowing investors and others to get a better understanding of GFG’s operating environment. Accordingly, readers should not place undue reliance on forward-looking statements. 

Forward-looking statements in this news release are made as of the date hereof and GFG assumes no obligation to update any forward-looking statements, except as required by applicable laws.

MISSISSAUGA, Ontario, Oct. 01, 2026 (GLOBE NEWSWIRE) — Bird Construction Inc. (TSX: BDT) announced today that it will release its 2026 third quarter financial results after market close on Wednesday, November 11, 2026. A conference call and live webcast to discuss the results will be held on Thursday, November 12, 2026 at 10:00 a.m. (ET).

Teri McKibbon, President and Chief Executive Officer, and Wayne Gingrich, Chief Financial Officer, will host the call.

Participants are invited to register for expedited access to the conference call: Registration Link

• Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

The live webcast will be held at: https://edge.media-server.com/mmc/p/dbjpgds5

The accompanying presentation of the 2026 third quarter financial results call and all related financial documents will be available after market close on Wednesday, November 11, 2026 at https://www.bird.ca/investors.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, contact:
Rachel Pattimore
Vice President, Investor Relations
Phone: (403) 520-2621
investor.relations@bird.ca

About Bird Construction

Bird (TSX: BDT) is a leading Canadian construction and maintenance company operating from coast-to-coast-to-coast. Servicing all of Canada’s major markets through a collaborative, safety-first approach, Bird provides a comprehensive range of construction services, self-perform capabilities, and innovative solutions to the industrial, buildings, and infrastructure markets. For over 105 years, Bird has been a people-focused company with an unwavering commitment to safety and a high level of service that provides long-term value for all stakeholders. www.bird.ca

CALGARY, Alberta, Oct. 01, 2026 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to confirm that its Board of Directors has declared a monthly dividend in the amount of $0.01 per share payable October 30, 2026, to shareholders of record on October 15, 2026. The dividend is designated as an eligible dividend for Canadian income tax purposes.

Dividend Reinvestment Plan (“DRIP”)
Petrus’ DRIP enables eligible shareholders to reinvest all or part of their cash dividends into additional common shares of the Company. Participation in the DRIP is optional. Eligible shareholders who elect to reinvest their cash dividends under the DRIP will receive common shares issued from treasury at a discount of 3% from the market price of the common shares.

To participate in the DRIP, registered shareholders must deliver a properly completed enrollment form to Odyssey Trust Company (“Odyssey”) before 4:00 p.m. (Calgary time) on the 5th business day immediately preceding a dividend record date. Beneficial shareholders who wish to participate in the DRIP should contact their broker or other nominee through which their Common Shares are held to determine their eligibility and provide appropriate enrollment instructions. Participation by shareholders that are not resident in Canada may be restricted.

A complete copy of the DRIP is available on the Company’s website at www.petrusresources.com and on Odyssey’s website at https://odysseytrust.com/faq/. A copy of the enrollment form for use by registered shareholders is available on Odyssey’s website at https://odysseytrust.com/faq/. For further information regarding the DRIP, please contact Odyssey at 1-888-290-1175 (Toll free in North America) or 1-587-885-0960.

ABOUT PETRUS
Petrus is a public Canadian oil and gas company focused on property exploitation, strategic acquisitions and risk-managed exploration in Alberta.

FOR FURTHER INFORMATION PLEASE CONTACT:
Ken Gray
President and Chief Executive Officer
T: 403-930-0889
E: kgray@petrusresources.com

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Ero Copper Corp. (TSX: ERO, NYSE: ERO) (“Ero” or the “Company”) will publish its third quarter 2026 operating and financial results on Monday, November 2, 2026, after market close. The Company will host a conference call to discuss the results on Tuesday, November 3, 2026 at 10:30 a.m. Eastern Time. A results presentation will be available for download via the webcast link and in the Presentations section of the Company’s website on the day of the conference call.

CONFERENCE CALL DETAILS

Date:		Tuesday, November 3, 2026
Time:		10:30 a.m. Eastern Time
Dial In:		Canada/USA Toll Free: 1-833-752-3380, International: +1-647-846-2821 Please dial in 5-10 minutes prior to the start of the call or pre-register using this link to bypass the live operator queue
Webcast:		To access the webcast, click here
Replay:		Canada/USA Toll Free: 1-855-669-9658, International: +1-412-317-0088 For country-specific dial-in numbers, click here
Replay Passcode:		1109122

ABOUT ERO

Ero is a Brazil-focused, growth-oriented mining company with a diversified portfolio of copper and gold assets. Headquartered in Vancouver, B.C., the Company operates two copper mines – the Caraíba Operations in Bahia State and the Tucumã Operation in Pará State – as well as the Xavantina Operations, a producing gold mine in Mato Grosso State. In addition to its operating assets, Ero is advancing the Furnas Copper-Gold Project, located in the mineral-rich Carajás Province in Pará State, through a definitive earn-in agreement with Vale Base Metals to acquire a 60% interest in the project.

Ero’s operating philosophy is grounded in a commitment to safety, operational excellence, and the responsible production of minerals essential for a better tomorrow. The Company’s shares are publicly traded on the Toronto Stock Exchange and the New York Stock Exchange under the symbol “ERO.” Additional information, including technical reports on the Company’s operations and projects, is available on the Company’s website (www.ero.com), SEDAR+ (www.sedarplus.ca), and on EDGAR (www.sec.gov).

FOR MORE INFORMATION, PLEASE CONTACT

Farooq Hamed, VP, Investor Relations
info@ero.com

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company’s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 106,000 shares of the Company’s common stock with a 10-year term and an exercise price of $88.32 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company“) is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the “Meadows Project“). 

The Meadows Project is represented by Saskatchewan Subsurface Mineral Permit #SMP273 (the “Permit“). Pursuant to the asset purchase agreement dated September 17, 2026 between the Company and Global Strategic Minerals Corp. (the “Vendor“), the Company acquired 100% of the Vendor’s interest in the Permit, all transferable technical information relating to the Meadows Project and all transferable governmental authorizations relating to the Permit (collectively, the “Purchased Assets“). For information regarding the Acquisition, please see the Company’s news release dated September 17, 2026.

About Vortex Energy Corp.

Vortex Energy Corp. is an exploration stage company engaged principally in the acquisition, exploration, and development of mineral properties in North America. The Company is currently advancing its Robinson River Salt Project comprised of a total of 942 claims covering 23,500 hectares located approximately 35 linear kms south of the town of Stephenville in the Province of Newfoundland & Labrador. The Robinson River Salt Project is prospective for both salt and hydrogen salt cavern storage. The Company is also currently advancing its Fire Eye Uranium Property in the Athabasca Basin, a region renowned for its uranium deposits.

On Behalf of the Board of Directors

Paul Sparkes
Chief Executive Officer, Director
+1 (778) 819-0164
info@vortexenergycorp.com 

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian securities legislation. Forward-looking information relates to future events or future performance and is often, but not always, identified by words such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “may”, “will”, “could” and similar expressions. All statements other than statements of historical fact may be forward-looking information. Forward-looking information is based on assumptions considered reasonable by management as of the date of this press release.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied, including risks inherent in mineral property acquisitions and the Company’s business.

There can be no assurance that forward-looking information will prove to be accurate. Readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and the Company undertakes no obligation to update or revise it, except as required by applicable securities laws. 

The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.

HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today the appointment of Rami Qasem to its board of directors effective October 1, 2026.

Mr. Qasem, 59, is a global energy, technology, and industrial executive with nearly 30 years of international leadership experience across oil and gas, industrial technology, digital transformation, artificial intelligence, and government partnerships. He served as Chief Executive Officer of APEX Industrial Services from 2025 to February 2026. He also served as Managing Director of Energy Capital Group during that same period. From 2023 to 2025, Mr. Qasem served as Executive Vice President and Chief Commercial Officer of BeyondAI, and during 2023, he also served as Chief Operations Officer of COP28 UAE. Prior to those roles, Mr. Qasem served as Executive Vice President and Chief Executive Officer, Digital Solutions of Baker Hughes from 2017 to 2023. Before then, Mr. Qasem spent 21 years at General Electric, beginning in 1996 and holding increasingly senior leadership positions, culminating as President and Chief Executive Officer, MENA & Turkey from 2002 to 2017, before transitioning to Baker Hughes following the 2017 merger of GE Oil & Gas and Baker Hughes. Mr. Qasem holds a Bachelor of Science degree in Electrical Engineering from Texas A&M University.

“I am delighted to welcome Rami to the KBR Board of Directors,” said KBR board Chair, President and CEO Stuart Bradie. “Rami brings nearly three decades of global leadership experience spanning energy, technology, digital solutions and operational excellence. His broad executive background and forward-looking perspective will be valuable additions to our board as KBR continues advancing differentiated technology solutions and creating long-term value for our stakeholders.”

The appointment further strengthens KBR’s governance and leadership as the company progresses toward the planned separation of its Mission Technology Solutions business in January 2027. KBR expects to provide additional separation-related updates in the coming months.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.

Forward Looking Statements
The statements in this press release that are not historical statements, including statements regarding future financial performance the planned spin-off of Trinzic, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

• Acquisition of a PharmaChoice Canada-bannered pharmacy in Western Canada completed at a purchase price of $1,300,000, subject to customary post-closing adjustments
• The acquisition increases PharmaCorp’s operating network to 17 pharmacies
• Previously announced purchase of the prescription files of an I.D.A.-bannered pharmacy in Western Canada completed at a purchase price of $475,000, subject to customary post-closing adjustments
• Canadian Imperial Bank of Commerce acquisition facility increased by $10 million, from $17.5 million to $27.5 million, providing additional capacity to fund acquisitions
• Non-binding letter of intent executed for the proposed acquisition of three PharmaChoice Canada-bannered pharmacies in Atlantic Canada

SASKATOON, Saskatchewan, Oct. 01, 2026 (GLOBE NEWSWIRE) — PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform, announced today that, further to its August 18, 2026, news release, it has completed the acquisition of a 100 per cent interest in a PharmaChoice Canada-bannered pharmacy located in Western Canada (the “Pharmacy Acquisition”), pursuant to the previously disclosed share purchase agreement dated August 10, 2026.

The Pharmacy Acquisition increases PharmaCorp’s overall store count to 17 pharmacies.

The aggregate purchase price for the Pharmacy Acquisition was $1,300,000, subject to customary post-closing adjustments, and was funded using the Corporation’s existing cash resources. The pharmacy was acquired from an arm’s length vendor group, and no finder’s fees were payable in connection with the Pharmacy Acquisition. The pharmacy will continue to be operated by its existing managing pharmacist during the transition period, supporting continuity and integration into the PharmaCorp platform.

The Corporation also announced that, further to the same August 18, 2026, news release, on September 11, 2026 it completed the acquisition of the prescription files, patient records and related operational data of an I.D.A.-bannered pharmacy located in Western Canada (the “File Acquisition”, and together with the Pharmacy Acquisition, the “Acquisitions”), pursuant to the previously disclosed asset purchase agreement dated August 7, 2026. The aggregate purchase price for the File Acquisition was $475,000, subject to customary post-closing adjustments, and was funded using the Corporation’s existing cash resources. The acquired files have been transferred to an existing PharmaCorp PharmaChoice Canada-bannered pharmacy located nearby and are being serviced from that location, consolidating patient volume into a pharmacy the Corporation already operates. The File Acquisition was an asset purchase and did not add a location to the Corporation’s operating network. The files were acquired from an arm’s length vendor, and no finder’s fees were payable in connection with the File Acquisition.

“We like opportunities to add prescription volume and cash flow to an existing pharmacy without the capital expense of adding another storefront,” said Alan Simpson, Executive Chairman of PharmaCorp. “We’ll continue to focus on our pharmacy acquisition strategy while also monitoring and evaluating prescription tuck-in opportunities when they arise. The expansion of our acquisition facility with CIBC from $17.5 million to $27.5 million provides additional capacity to fund future acquisitions.”

Credit Facility

The Corporation also announced that, further to its news release dated August 13, 2025, it has exercised the previously announced $10,000,000 accordion feature under its acquisition term facility with Canadian Imperial Bank of Commerce (“CIBC”). Pursuant to an amendment dated September 30, 2026 to the credit agreement between the Corporation and CIBC dated August 12, 2025, the credit limit of the acquisition term facility has been increased from $17,500,000 to $27,500,000. Amounts available under the facility may be used to finance acquisitions of pharmacy businesses, including the assets or shares of a pharmacy business, and acquisitions of real property in Canada for the purpose of operating a pharmacy business, on the terms and conditions set out in the credit agreement.

Acquisition Pipeline Update

The table below sets out the status of each non-binding letter of intent previously disclosed by the Corporation and not reported as completed before the date of this news release, together with the further letter of intent described below.

LOI date	Opportunity	Definitive agreement	Status
February 27, 2026, replaced by letter of intent dated June 19, 2026	PharmaChoice Canada-bannered pharmacy, Western Canada (share purchase)	Share purchase agreement dated August 10, 2026	Completed October 1, 2026; store count increased to 17
March 23, 2026	Pharmacy, Western Canada	Not executed	No longer being pursued
June 23, 2026	Remedy’sRx-bannered pharmacy, Western Canada (share purchase)	Not executed	No longer being pursued
June 29, 2026	I.D.A.-bannered pharmacy prescription files, Western Canada (asset purchase)	Asset purchase agreement dated August 7, 2026	Completed September 11, 2026; no additional location
July 23, 2026	PharmaChoice Canada-bannered pharmacy, Western Canada (share purchase)	Pending	Due diligence and documentation in progress
September 11, 2026	Three PharmaChoice Canada-bannered pharmacies, Atlantic Canada (share purchase)	Pending	Due diligence and documentation in progress

The Corporation has executed a non-binding letter of intent dated September 11, 2026 for the proposed acquisition of three PharmaChoice Canada-bannered pharmacies located in Atlantic Canada.

The Corporation is no longer pursuing the proposed acquisitions contemplated by the non-binding letters of intent dated March 23, 2026 and June 23, 2026. Following completion of the Acquisitions and those decisions, two non-binding letters of intent remain outstanding (the “Outstanding LOIs”). The proposed acquisitions contemplated by the Outstanding LOIs (the “Proposed LOI Acquisitions”) are non-binding and remain subject to the completion of satisfactory due diligence and the negotiation and execution of definitive purchase agreements. There can be no assurance that any of the Proposed LOI Acquisitions will be completed as proposed, or at all. No finder’s fees are payable in respect of the Proposed LOI Acquisitions. Each of the Proposed LOI Acquisitions is with an arm’s length vendor.

About PharmaCorp Rx Inc.

PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support and operational expertise, PharmaCorp is building a national network of community pharmacies under the PharmaChoice Canada banner.

PharmaCorp currently operates 17 PharmaChoice Canada-bannered pharmacies and intends to continue acquiring both PharmaChoice Canada-bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada, where applicable. PharmaCorp shares trade on the TSX Venture Exchange under the symbol PCRX.

PharmaCorp welcomes discussions with pharmacy owners considering succession or sale. For more information about PharmaCorp’s acquisition program and process, please visit www.PharmaCorpRx.ca or contact the company confidentially. PharmaCorp is committed to seamless transitions that protect pharmacy owners’ legacies and continue serving their communities.

For further information, please contact:

Investor Relations
LodeRock Advisors Inc.
Adam Peeler
adam.peeler@pharmacorprx.ca
Tel: (416) 427-1235

Neither the TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in the policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release contains “forward-looking information” regarding the Corporation within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information.

In particular, this news release contains forward-looking information relating to: the continued operation of the pharmacy acquired under the Pharmacy Acquisition by its existing managing pharmacist during the transition period and its integration into the PharmaCorp platform; the continued servicing of the files acquired under the File Acquisition from an existing PharmaCorp pharmacy and the expected consolidation of patient volume into that location; the Outstanding LOIs and the Proposed LOI Acquisitions, including the negotiation and execution of definitive purchase agreements in respect of the Proposed LOI Acquisitions, the expected terms of the Proposed LOI Acquisitions, the consideration for the Proposed LOI Acquisitions, the expected conditions (including due diligence) and the satisfaction of those conditions for the completion of the Proposed LOI Acquisitions, and the potential completion of the Proposed LOI Acquisitions; the availability of advances under the acquisition term facility to fund future acquisitions, including the satisfaction of the conditions to such advances and the receipt of any required CIBC approvals; the Corporation’s expectation that it will continue to pursue both pharmacy acquisitions and prescription file purchases where they arise; the Corporation’s acquisition pipeline and anticipated pace of future acquisitions; the continued acquisition, integration and operation of pharmacies across Canada; and the Corporation’s acquisition framework, capital allocation strategy and plans for growth.

This forward-looking information reflects current beliefs and is based on information currently available to the management of the Corporation and on assumptions the Corporation believes are reasonable. These assumptions include, but are not limited to: the successful integration and operation of the pharmacy acquired under the Pharmacy Acquisition and of the files acquired under the File Acquisition; the retention of the existing managing pharmacist during the transition period; the execution of definitive purchase agreements in respect of the Proposed LOI Acquisitions; the completion of satisfactory due diligence and the satisfaction or waiver of customary closing conditions in respect of the Proposed LOI Acquisitions; the receipt of all required approvals for the Proposed LOI Acquisitions, including any board approvals, regulatory approvals or third-party consents; market acceptance of the Proposed LOI Acquisitions; the Corporation’s continued compliance with the terms of the credit agreement with CIBC, including its financial covenants, and the satisfaction of the conditions to advances under the acquisition term facility; the continued availability of pharmacies and prescription files for purchase by the Corporation at prices satisfactory to the Corporation; and the volume of acquisition opportunities presented to the Corporation being equal to or greater than historical volumes.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Corporation to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delays or failures to receive board, third-party or regulatory approvals; competition; changes in legislation, including pharmacy regulation, affecting the Corporation; the timing and availability of external financing on acceptable terms; the inability of the Corporation to satisfy the conditions to, or obtain any required approval of CIBC for, advances under the acquisition term facility; conclusions of economic evaluations and appraisals; and a lack of qualified, skilled labour or the loss of key individuals.

A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Corporation’s disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although the Corporation has attempted to identify important risks and factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which it is based will occur.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement and represents the expectations of the Corporation as of the date of this news release. Accordingly, it is subject to change after such date. The Corporation expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.